Immunoglobulin G-degrading enzyme of Streptococcus pyogenes (IdeS) with INN name imlifidase, is an enzyme that specifically cleaves immunoglobulin G (IgG). Our strategy takes advantage of the ability of imlifidase to specifically and efficiently inactivate human IgG antibodies, to prevent and treat patients that have developed pathogenic IgG. Imlifidase-mediated IgG degradation is a new therapeutic principle for treatment of IgG-driven human diseases.
Imlifidase has been pre-clinically tested regarding efficacy and safety. The therapeutic effect of imlifidase has been studied in various disease models; e.g. collagen antibody induced arthritis (CAIA), idiopathic thrombocytopenic purpura (ITP) and Goodpasture’s disease (GP). Imlifidase was found to efficiently neutralize IgG in all three models. Experiments on serum collected from highly sensitized kidney patients clearly demonstrated that imlifidase rapidly reduced the level of anti-HLA antibodies and that imlifidase could turn a positive cross-match into a negative.
This was a strong support for us to further investigate imlifidase for desensitization of patients before transplantation.
Our initial clinical studies are focused on desensitization of HLA-immunized patients before kidney transplantation and treatment of antibody mediated graft rejection. Beyond transplantation, we have identified therapeutic options for imlifidase treatment within the areas of neurology, nephrology and hematology.